Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 80% Improvement Relative Risk ΔSHOCS-COVID 50% primary SHOCS-COVID 71% NEWS-2 67% Hospitalization time 26% Mareev et al. Colchicine for COVID-19 LATE TREATMENT Is late treatment with colchicine beneficial for COVID-19? Retrospective 43 patients in Russia Lower mortality (p=0.49) and improved recovery (p=0.064), not stat. sig. Mareev et al., Kardiologiia, doi:10.18087/cardio.2021.2.n1560 Favors colchicine Favors control
Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study
Mareev et al., Kardiologiia, doi:10.18087/cardio.2021.2.n1560
Mareev et al., Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus.., Kardiologiia, doi:10.18087/cardio.2021.2.n1560
Feb 2021   Source   PDF  
  All Studies   Meta
Small trial with 21 colchicine patients and 22 control patients in Russia, showing improved recovery with treatment. The trial was originally an RCT, however randomization to the control arm was stopped after 5 patients, and 17 retrospective patients were added for comparison.
risk of death, 79.6% lower, RR 0.20, p = 0.49, treatment 0 of 21 (0.0%), control 2 of 22 (9.1%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
ΔSHOCS-COVID, 50.0% lower, RR 0.50, p = 0.06, treatment 21, control 22, ΔSHOCS-COVID score, primary outcome.
SHOCS-COVID, 71.4% lower, RR 0.29, p = 0.002, treatment 21, control 22, SHOCS-COVID score.
NEWS-2, 66.7% lower, RR 0.33, p = 0.06, treatment 21, control 22, inverted to make RR<1 favor treatment, NEWS-2 score.
hospitalization time, 25.7% lower, relative time 0.74, p = 0.08, treatment 21, control 22.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mareev et al., 28 Feb 2021, retrospective, Russia, peer-reviewed, 21 authors, dosage 1mg days 1-3.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: § EDITORIAL ARTICLES Mareev V. Yu.1,2, Orlova Ya.A.1,2, Plisyk A.G.1,2, Pavlikova E.P.1,2, Akopyan Z.A.1,2, Matskeplishvili S.Т.1, Malahov P. S.1, Krasnova T. N.1,2, Seredenina E.M.1,2, Potapenko A.V.1,2, Agapov M.A.1,2, Asratyan D.A.1, Dyachuk L.I.1,2, Samokhodskaya L. M.1,2, Mershina Е. А.1,2, Sinitsyn V. E.1,2, Pakhomov P. V.2, Zhdanova E.A.1,2, Mareev Yu.V.3,4, Begrambekova Yu. L.1,2, Kamalov А. А.1,2 Medical Research and Educational Center of the M. V. Lomonosov Moscow State University, Moscow, Russia Faculty of Fundamental Medicine, Lomonosov Moscow State University, Russia 3 National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia 4 Robertson Centre for Biostatistics, Glasgow, Great Britain 1 2 Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study Actuality The course of the novel coronavirus disease (COVID-19) is unpredictable. In some cases, it manifests as increasing inflammation that leads to a cytokine storm and irreversible progression to acute respiratory syndrome, which is associated with the risk of death. Thus, proactive anti-inflammatory therapy remains an open, serious question for patients with COVID-19 and pneumonia. This is especially true for those patients who still have signs of inflammation on days 7–9 of the disease. These signs include elevated C-reactive protein (CRP) >60 mg / dl and at least two of the four clinical signs: 1) fever >37.5°C; 2) persistent cough; 3) dyspnea (RR >20 brpm) and / or reduced arterial oxygen saturation (SaO2) <94 % when breathing atmospheric air. We designed the randomized trial: COLchicine versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients with COVID-19 (COLORIT). We present here data comparing patients who received colchicine with those who did not receive this specific anti-inflammatory therapy. Results of the comparison of colchicine, ruxolitinib, and secukinumab will be presented later. Objective Compare efficacy and safety of colchicine in the management of patients with COVID-19 to that without specific anti-inflammatory therapy. Material and Methods Initially, 20 people were expected to be randomized in the control group. However, enrollment to the control group was discontinued after the inclusion of 5 patients due to the risk of severe deterioration in the absence of anti-inflammatory treatment. Therefore, 17 patients, who had not received antiinflammatory therapy when previously treated in the MSU Medical Research and Educational Center, were also included in the control group. The effects of treatment were assessed on day 12 after inclusion or at discharge if discharge occurred earlier than on day 12. The primary endpoint was changes in the SHOCS-COVID score, which includes an assessment of the patient’s clinical condition, CT score of lung tissue damage, the severity of systemic inflammation as indicated by changes in CRP, and the risk of thrombotic complications as indicated by D-dimer [1]. Results In the colchicine group, the median SHOCS score decreased from 8 to 2 (p=0.017), i.e., from a moderate to a mild degree. In the control group, the change in the SHOCS-COVID score was minimal and statistically insignificant. In patients treated with colchicine, CRP decreased rapidly from 99.4 and normalized at 4.2 mg / dl (p<0.001). In the control group, CRP decreased moderately but..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop